-
Guangzhou Baiyunshan Halts Spinning-off of Guangzhou Pharmaceutical Amid HK Capital Shifts
•
China-based Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) has announced the suspension of the spinning-off of its subsidiary Guangzhou Pharmaceutical Co., Ltd. This decision comes after considering the reply expiration date from the China Securities Regulatory Commission (CSRC) and changes in the Hong Kong capital market. Regulatory TimelineGuangzhou Pharma first…
-
Cuban-Chinese Pharma Synergy: Joint R&D and Sales Initiative Targets USD 24.53 Billion in Sales
•
In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered into a letter of intent with BioCubaFarma, Cuba’s leading state-owned pharmaceutical company. This strategic alliance is aimed at joint research and development (R&D), manufacturing, and sales of cutting-edge pharmaceutical products in China, with a particular…
-
Guangzhou Pharma and BioCubaFarma Chart New Course with Joint Biologics R&D and Exchange Deal
•
Guangzhou Pharmaceutical Holdings Ltd., a prominent player in China’s pharmaceutical sector, has inked a strategic letter of intent with BioCubaFarma, Cuba’s foremost state-owned pharmaceutical juggernaut, to embark on a joint venture in research and development (R&D), manufacturing, and commercialization of avant-garde pharmaceutical products within the Chinese market, with a spotlight…
